Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Companies / CorrectSequence Therapeutics
Entity

CorrectSequence Therapeutics

Tracked across 1 events · 8 articles · First seen Jun 02, 2026 · Last active Jun 02, 2026

Sentiment
90
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 90
Tech
CorrectSequence CS-206 Sickle Cell Data
CorrectSequence Therapeutics, a clinical-stage biotechnology company, announced positive 15-month follow-up data for its high-precision base-editing therapy, CS-206, for Sickle cell disease. The first patient treated in China, a 21-year-old woman from Nigeria, has remained free…
Impact: CorrectSequence Therapeutics has reported positive 15-month follow-up data for its CS-206 therapy, demonstrating its efficacy and safety in treating sickle cell disease. This success enhances the company's reputation and potential for commercialization.
Jun 02, 2026 · 8 articles
Key Actions (2)
90 CorrectSequence Therapeutics reported positive dataCorrectSequence CS-206...
80 CorrectSequence Therapeutics accelerating clinical developmentCorrectSequence CS-206...
NEWSDESK
Track CorrectSequence Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.